Das Unternehmen BioCryst Pharmaceuticals, Inc. (BCRX) übertrifft die Erwartungen um knapp 400%.
BioCryst Q4 results top Street on flu drug sales
Q4 EPS $0.35 vs est $0.09
Q4 rev $54.9 mln vs est $23.7 mln
Shares up 10 pct in pre-market trade
Feb 4 (Reuters) - BioCryst Pharmaceuticals Inc (BCRX.O) reported fourth-quarter results that topped market expectations, driven by an increase in sales of its key influenza drug, sending its shares up as much as 10 percent in pre-market trade.
For the quarter, the company posted a net income of $15.2 million, or 35 cents a share, compared with $10.1 million, or 26 cents a share, a year earlier.
Total revenue rose 60 percent to $54.9 million, primarily bolstered by a $22.5 million order of 10,000 courses of BioCryst's intravenous drug peramivir from the Department of Health and Human Services (HHS).
Last October, the company's drug received an emergency use authorization from U.S. health regulators for treating the H1N1 flu.
Analysts on average expected the company to earn 9 cents a share, on revenue of $23.7 million, according to Thomson Reuters I/B/E/S.
For 2010, BioCryst expects cash use to be between $25 million and $30 million.
Shares of the company were up 10 percent at $7.97 in pre-market trade. They had closed at $7.23 Wednesday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Maju Samuel)
www.reuters.com/article/idCNSGE6130HG20100204?rpc=44
BioCryst Q4 results top Street on flu drug sales
Q4 EPS $0.35 vs est $0.09
Q4 rev $54.9 mln vs est $23.7 mln
Shares up 10 pct in pre-market trade
Feb 4 (Reuters) - BioCryst Pharmaceuticals Inc (BCRX.O) reported fourth-quarter results that topped market expectations, driven by an increase in sales of its key influenza drug, sending its shares up as much as 10 percent in pre-market trade.
For the quarter, the company posted a net income of $15.2 million, or 35 cents a share, compared with $10.1 million, or 26 cents a share, a year earlier.
Total revenue rose 60 percent to $54.9 million, primarily bolstered by a $22.5 million order of 10,000 courses of BioCryst's intravenous drug peramivir from the Department of Health and Human Services (HHS).
Last October, the company's drug received an emergency use authorization from U.S. health regulators for treating the H1N1 flu.
Analysts on average expected the company to earn 9 cents a share, on revenue of $23.7 million, according to Thomson Reuters I/B/E/S.
For 2010, BioCryst expects cash use to be between $25 million and $30 million.
Shares of the company were up 10 percent at $7.97 in pre-market trade. They had closed at $7.23 Wednesday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Maju Samuel)
www.reuters.com/article/idCNSGE6130HG20100204?rpc=44